Targeted Decorin Gene Therapy Delivered with Adeno-Associated Virus Effectively Retards Corneal Neovascularization In Vivo
Authors:
Open Access
- 19 October 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (10) , e26432
Abstract
Decorin, small leucine-rich proteoglycan, has been shown to modulate angiogenesis in nonocular tissues. This study tested a hypothesis that tissue-selective targeted decorin gene therapy delivered to the rabbit stroma with adeno-associated virus serotype 5 (AAV5) impedes corneal neovascularization (CNV) in vivo without significant side effects. An established rabbit CNV model was used. Targeted decorin gene therapy in the rabbit stroma was delivered with a single topical AAV5 titer (100 µl; 5×1012 vg/ml) application onto the stroma for two minutes after removing corneal epithelium. The levels of CNV were examined with stereomicroscopy, H&E staining, lectin, collagen type IV, CD31 immunocytochemistry and CD31 immunoblotting. Real-time PCR quantified mRNA expression of pro- and anti-angiogenic genes. Corneal health in live animals was monitored with clinical, slit-lamp and optical coherence tomography biomicroscopic examinations. Selective decorin delivery into stroma showed significant 52% (p<0.05), 66% (p<0.001), and 63% (p<0.01) reduction at early (day 5), mid (day 10), and late (day 14) stages of CNV in decorin-delivered rabbit corneas compared to control (no decorin delivered) corneas in morphometric analysis. The H&E staining, lectin, collagen type IV, CD31 immunostaining (57–65, p<0.5), and CD31 immunoblotting (62–67%, p<0.05) supported morphometric findings. Quantitative PCR studies demonstrated decorin gene therapy down-regulated expression of VEGF, MCP1 and angiopoietin (pro-angiogenic) and up-regulated PEDF (anti-angiogenic) genes. The clinical, biomicroscopy and transmission electron microscopy studies revealed that AAV5–mediated decorin gene therapy is safe for the cornea. Tissue-targeted AAV5-mediated decorin gene therapy decreases CNV with no major side effects, and could potentially be used for treating patients.Keywords
This publication has 39 references indexed in Scilit:
- Anti-inflammatory protein TSG-6 reduces inflammatory damage to the cornea following chemical and mechanical injuryProceedings of the National Academy of Sciences, 2010
- AAV serotype influences gene transfer in corneal stroma in vivoExperimental Eye Research, 2010
- Ocular Drug DeliveryThe AAPS Journal, 2010
- Novel aspects of corneal angiogenic and lymphangiogenic privilegeProgress in Retinal and Eye Research, 2010
- Transduction efficiency of AAV 2/6, 2/8 and 2/9 vectors for delivering genes in human corneal fibroblastsBrain Research Bulletin, 2010
- MT1-MMP-Mediated Cleavage of Decorin in Corneal AngiogenesisJournal of Vascular Research, 2009
- Regulation of Blood Vessel versus Lymphatic Vessel Growth in the CorneaInvestigative Ophthalmology & Visual Science, 2009
- Topical Bevacizumab in the Treatment of Corneal NeovascularizationArchives of Ophthalmology (1950), 2009
- Clinical and research applications of anterior segment optical coherence tomography – a reviewClinical & Experimental Ophthalmology, 2009
- Nanoparticles Sustain Expression of Flt Intraceptors in the Cornea and Inhibit Injury-Induced Corneal AngiogenesisInvestigative Ophthalmology & Visual Science, 2007